US Patent Issued to The Johns Hopkins University on July 28 for "Engineered immune cells to target SARS-CoV2" (Maryland Inventors)

ALEXANDRIA, Va., July 28 -- United States Patent no. 12,691,146, issued on July 28, was assigned to The Johns Hopkins University (Baltimore).

"Engineered immune cells to target SARS-CoV2" was invented by Challice Bonifant (Baltimore) and Ilias Christodoulou (Baltimore).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are, inter alia, methods, compositions and kits for treating or preventing coronaviruses, e.g., SARS-CoV-2. Also included herein are kits for treating or preventing coronaviruses, e.g., SARS-CoV-2."

The patent was filed on Sept. 30, 2021, under Application No. 18/029,592.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/np...